i-THYMUS The i-Thymus: wielding the potential of gene therapy, cell therapy and induced pluripotent stem cells for the regeneration of the thymus and the adaptive immune system
- Coordinator
- Genewity BV, Netherlands
- Runs
- 1 November 2023 to 31 October 2025
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €3.6m
- Partners
- 2 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190124491
What the project is doing
In the project's own words, from its summary on CORDIS.
Each year, >250 babies are born without a thymus. These babies have a life expectancy of 2-3 years. The only cure is transplantation of thymus tissue, but this has a 30% mortality rate and costs almost >€2.5M. We developed i-Thymus, a revolutionary cure based on the patient’s own cells leveraging innovative gene therapy to generate thymus organoids that can be implanted minimally invasively in the patient (Fig. 1). We have already shown this works in functional proof of concept in vivo.
With this EIC Accelerator, we will finalise development to enter the clinic for a Phase I/II trial, to enter the EU market with a pharma partner by 2028. After rapid market entry with ODD for complete DiGeorge syndrome, we will leverage this clinical success and our first revenues to develop i-Thymus for unmet needs of hundreds of thousands of other patients, starting with AML patients who have lost thymus function after high-dose chemotherapy for stem cell transplantation.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Genewity BV | Leiden | Netherlands | Coordinator |
| Genewity Holding BV | Leiden | Netherlands | Third party |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI